Neurocrine Biosciences Inc (NBIX) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Neurocrine Biosciences Inc   (NASDAQ: NBIX)
 

Neurocrine Biosciences Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Neurocrine Biosciences Inc inventory turnover ratio, the Neurocrine Biosciences Inc 's ability to sell and replace its inventory in the third quarter 2026, sequentially increased to 1.07 in the third quarter 2026, NBIX's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Neurocrine Biosciences Inc in Sep 30 2026 quarter, has decreased to 341 days, compare to 415 days, in the Jun 30 2026 quarter.

Within Healthcare sector 306 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1283 in the second quarter 2026, to 1828.

NBIX Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Neurocrine Biosciences Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBIX Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth -4.62 % 83.13 % 9.14 % 20.21 % 51.31 %
Y / Y Cost of Sales Growth 104.62 % 125.24 % 50 % 89.25 % 62.5 %
Inventory Turnover Ratio (TTM) 1.07 0.88 0.84 0.79 0.69
NBIX's Total Ranking # 1828 # 1283 # 479 # 458 #
Average inventory processing period 341 414 433 463 530
Seq. Inventory Growth -36.56 % 61.55 % -6.52 % -0.43 % 21.79 %
Seq. Cost of Sales Growth 14.66 % 68.12 % -21.59 % 35.38 % 26.21 %




Inventory Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 307
Overall Market # 1828

Inventory Turnover Ratio Statistics
High Average Low
1.21 0.74 0.43
(Sep 30 2023)   (Mar 31 2021)



NBIX Company Profile >> Back to NBIX Efficiency Comparisons >> Compare NBIX Inventory Turnover Ratio to its Competitors

Financial Statements
Neurocrine Biosciences Inc 's Inventories $ 66 Millions Visit NBIX's Balance sheet
Neurocrine Biosciences Inc 's Cost of Revenues TTM $ 81 Millions Visit NBIX's Income Statement
What are NBIX's Sales? Visit NBIX's Sales by Segment

Other Inventory Turnover Ratios
Neurocrine Biosciences Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Biotechnology & Pharmaceuticals Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
NBIX's Inventory Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for NBIX's Competitors
Inventory Turnover Ratio for NBIX's Suppliers
Inventory Turnover Ratio for NBIX's Customers

You may also want to know
NBIX's Sales Growth Rates NBIX's Pe Price to earnings ratio NBIX's Receivables Turnover Ratio NBIX's Stock Quote
NBIX's Net Income Growth Rates NBIX's Ps Price to Sales ratio NBIX's Sales per Employee NBIX's Asset Turnover Ratio
NBIX's Net Margin NBIX's Pb Price to Book ratio NBIX's Financial Strength Ratios NBIX's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Gilead Sciences Inc   3.30 $ 6,219.000  Millions$ 1,884  Millions
Mimedx Group Inc   2.98 $ 70.562  Millions$ 24  Millions
Ligand Pharmaceuticals Incorporated  2.93 $ 34.495  Millions$ 12  Millions
Neogen Corporation  2.89 $ 464.774  Millions$ 161  Millions
Biomerica Inc   2.65 $ 4.297  Millions$ 2  Millions
Dexcom Inc   2.65 $ 1,867.500  Millions$ 705  Millions
Angiodynamics Inc   2.50 $ 142.709  Millions$ 57  Millions
Pro dex Inc   2.45 $ 53.753  Millions$ 22  Millions
Illumina Inc   2.36 $ 1,458.000  Millions$ 618  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions
Johnson and Johnson  2.17 $ 32,222.000  Millions$ 14,824  Millions
Glaukos Corp  2.13 $ 131.180  Millions$ 62  Millions
Organon and Co   2.08 $ 2,859.000  Millions$ 1,371  Millions
Repligen Corp  2.07 $ 372.472  Millions$ 180  Millions
Boston Scientific Corporation  2.06 $ 6,502.000  Millions$ 3,153  Millions
Bausch and Lomb Corp  2.01 $ 1,986.000  Millions$ 990  Millions
Clearpoint Neuro Inc   1.98 $ 17.564  Millions$ 9  Millions
Intuitive Surgical Inc   1.91 $ 3,799.300  Millions$ 1,986  Millions
Indivior Pharmaceuticals Inc   1.88 $ 208.000  Millions$ 111  Millions
Tenet Healthcare Corp  1.88 $ 642.000  Millions$ 342  Millions
Iradimed Corporation  1.78 $ 21.878  Millions$ 12  Millions
Axsome Therapeutics Inc   1.67 $ 58.422  Millions$ 35  Millions
Insmed Inc  1.66 $ 237.067  Millions$ 143  Millions
Stryker Corp  1.66 $ 9,116.000  Millions$ 5,499  Millions
Integra Lifesciences Holdings Corp  1.62 $ 789.329  Millions$ 486  Millions
Conmed Corporation  1.61 $ 580.951  Millions$ 361  Millions
Axogen inc   1.49 $ 68.923  Millions$ 46  Millions

Date modified: 2026-11-03T10:01:40+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.